Dr John Charles Edlin, MD in Dallas, TX - Counselor

Dr John Charles Edlin, MD is a Counselor - Mental Health physician based in Dallas, Texas. Dr John Charles Edlin is licensed to practice in * (Not Available) (license number ) and his current practice location is 12800 Hillcrest Rd, Suite 216, Dallas, Texas. He can be reached at his office (for appointments etc.) via phone at (972) 239-9252.

NPI number for Dr John Charles Edlin is 1114936614 and his current mailing address is 12800 Hillcrest Rd, Suite 216, Dallas, Texas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1114936614.

Contact Information

	Dr John Charles Edlin, MD
	12800 Hillcrest Rd, Suite 216, Dallas, TX 75230-1524
	(972) 239-9252
	(972) 404-9609

Physician's Profile

Full Name	Dr John Charles Edlin
Gender	Male
Speciality	Counselor - Mental Health
Location	12800 Hillcrest Rd, Dallas, Texas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1114936614
Provider Enumeration Date: 08/05/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr John Charles Edlin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1114936614	NPI	-	NPPES
886542	Other	TX	BLUE CROSS BLUE SHIELD

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207QA0000X	Family Medicine - Adolescent Medicine	E1307 (Texas)	Primary
2080A0000X	Pediatrics - Adolescent Medicine	E1307 (Texas)	Primary
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr John Charles Edlin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr John Charles Edlin, MD 12800 Hillcrest Rd, Suite 216, Dallas, TX 75230-1524 Ph: (972) 239-9252	Dr John Charles Edlin, MD 12800 Hillcrest Rd, Suite 216, Dallas, TX 75230-1524 Ph: (972) 239-9252

News Archive

U of A professor receives $542,000 from NSERC for drinking water research

Water is something people can't live without, that's why it's important that Xing Fang Li finds out what is in our tap water that may pose a disease risk. The researcher from the Faculty of Medicine & Dentistry at the University of Alberta just received $542,000 from the Natural Sciences and Engineering Research Council of Canada for drinking water research.

Some U.S. troops stay in Haiti; Aid officials prepare for rainy season

Kenneth Merten, the U.S. ambassador to Haiti, said on Thursday that American troops would stay in the country to aid in its recovery, Agence France-Presse reports. "There are about 6,500 soldiers in Haiti at the moment. There were some 20,000 for the emergency effort launched in the wake of January 12," Merten said. "What is planned for the moment is more and more staff from USAID on the ground and fewer and fewer troops. Gradually, they'll leave. In my opinion, we will need some American troops to stay here for the foreseeable future" (2/25).

Medical imaging website compiles list of hottest clinical procedures in imaging for AD

AuntMinnie.com, the respected medical imaging website, has compiled a list of the "hottest clinical procedures" in imaging, such as molecular breast imaging and PET scans for Alzheimer's disease.

OCF to offer free oral cancer screenings in April 2012

Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments.

Dr John Charles Edlin, MD - Counselor in Dallas, TX